Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Genmab ADR (NASDAQ: GMAB) closed the day trading at $20.68 down -2.27%% from the previous closing price of $21.16. In other words, the price has decreased by -$2.27% from its previous closing price. On the day, 3.56 million shares were traded.
Ratios:
For a better understanding of GMAB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.92. For the most recent quarter (mrq), Quick Ratio is recorded 5.32 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Leerink Partners Upgraded its Market Perform to Outperform on February 13, 2025, while the target price for the stock was maintained at $27.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 17 ’25 when Klimovsky Judith V bought 1,300 shares for $51.69 per share.
Valuation Measures:
As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.73, and their Forward P/E ratio for the next fiscal year is 11.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.94 while its Price-to-Book (P/B) ratio in mrq is 2.48.
Stock Price History:
Over the past 52 weeks, GMAB has reached a high of $28.56, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is -0.53%, while the 200-Day Moving Average is calculated to be -4.45%.
Shares Statistics:
A total of 635.50M shares are outstanding, with a floating share count of 615.07M. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.62% stake in the company.
